LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Catalyst Biosciences (CBIO) on December 15 and set a price target of $18.00. The company’s shares closed last Monday at $6.66.
According to TipRanks.com, Slutsky is a 4-star analyst with an average return of 30.1% and a 68.9% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Aeglea Biotherapeutics, Sierra Oncology, and BELLUS Health.
Catalyst Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $18.00, representing a 176.5% upside. In a report issued on December 2, Raymond James also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8.94 and a one-year low of $3.43. Currently, Catalyst Biosciences has an average volume of 273.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on August 20, 2015 and is headquartered in South San Francisco, CA.
